Exploring the use of the medicinal leech: A clinical risk-benefit analysis

被引:103
|
作者
deChalain, TMB [1 ]
机构
[1] EMORY UNIV,DEPT PLAST SURG,ATLANTA,GA 30322
关键词
D O I
10.1055/s-2007-1006471
中图分类号
R61 [外科手术学];
学科分类号
摘要
The medicinal leech, Hirudo medicinalis, has been used with increasing frequency for salvage of compromised pedicled flaps and microvascular free-tissue transfers. The data pertaining to 18 cases in which flap salvage with leeches was attempted were reviewed and contrasted with the data from 108 published cases from other centers. A further analysis isolated and examined 19 cases in which infection, secondary to leech utilization, supervened. Results suggested that successful salvage of tissue with leeches occurs in 70 to 80 percent of cases. In contrast, the infection rate of most series is between 7 and 20 percent and, when a clinically significant infection occurs, the flap salvage rate drops to 30 percent or less. In addition to infection, the risks of leech therapy include blood loss, which may require replacement transfusion, loss of leeches into body orifices and spaces, allergic reactions, and adverse psychological responses. Clinical indications and contraindications, and strategies to reduce the risks of leech usage, are discussed. Conclusions are that leeches are best used early, and in accordance with an accepted institutional protocol. For each case, the potential risks and benefits must be rigorously assessed and honestly applied.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [41] RISK-BENEFIT AND COST-BENEFIT-ANALYSIS - REPLY
    NEMETZ, PN
    VINING, A
    POLICY SCIENCES, 1982, 14 (03) : 299 - 302
  • [42] Clinical risk-benefit assessment of dopamine agonists
    Moeller, J. C.
    Eggert, K. M.
    Unger, M.
    Odin, P.
    Chaudhuri, K. R.
    Oertel, W. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 15 - 23
  • [43] Tranexamic acid: the importance of correct use and individualized risk-benefit analysis
    Pekrul, Isabell
    Schachtner, Thomas
    Zwissler, Bernhard
    Moehnle, Patrick
    ANAESTHESIST, 2021, 70 (07): : 616 - 617
  • [44] Exploring subjective risk-benefit perception as an integral component in risk communication
    Lohmann, Mark
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33
  • [45] Unbalanced risk-benefit analysis of ADHD drugs
    Faltinsen, Erlend G.
    Gluud, Christian
    Simonsen, Erik
    Zwi, Morris
    Storebo, Ole Jakob
    LANCET PSYCHIATRY, 2018, 5 (11): : 870 - 870
  • [46] A Risk-Benefit Analysis of Methadone Maintenance Treatment
    James Bell
    Deborah Zador
    Drug Safety, 2000, 22 : 179 - 190
  • [47] Chiropractic care: A flawed risk-benefit analysis?
    Hurwitz, EL
    Meeker, WC
    Smith, M
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2003, 93 (04) : 523 - 524
  • [48] RISK-BENEFIT ANALYSIS FOR TOXIC-CHEMICALS
    WILSON, R
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 1980, 4 (04) : 370 - 383
  • [50] The dummies' guide to risk-benefit analysis of vaccines
    Puliyel, JM
    PEDIATRICS, 2002, 110 (01) : 193 - 193